A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 Versus Placebo in Adults With Relapsing Multiple Sclerosis (ENSURE-2)
Latest Information Update: 24 Oct 2024
Price :
$35 *
At a glance
- Drugs Vidofludimus calcium (Primary)
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms ENSURE-2
- Sponsors Immunic
- 22 Oct 2024 According to an Immunic media release,company announced a positive outcome of the non-binding, interim futility analysis of its phase 3 ENSURE program
- 08 Aug 2024 According to an Immunic media release, an interim futility analysis of the ENSURE program is expected in the fourth quarter of 2024. Company is on track with phase 3 ENSURE program in RMS and expect to complete the first ENSURE trial in the second quarter of 2026 and the second ENSURE trial in the second half of 2026.
- 08 May 2024 According to an Immunic media release, read outs of this second ENSURE trial is anticipate in the second half of 2026